Prosecution Insights
Last updated: August 17, 2026
Application No. 18/265,479

METHOD AND SYSTEM FOR SIMULTANEOUS INTERPRETATION OF TAXONOMIC DISTRIBUTION AND REPLICATION RATES OF MICROBIAL COMMUNITIES

Non-Final OA §101§112
Filed
Jun 06, 2023
Priority
Dec 09, 2020 — IN 202021053578 +1 more
Examiner
LIN, JERRY
Art Unit
Tech Center
Assignee
Tata Group
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
605 granted / 837 resolved
+12.3% vs TC avg
Moderate +15% lift
Without
With
+15.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 11m
Avg Prosecution
25 currently pending
Career history
855
Total Applications
across all art units

Statute-Specific Performance

§101
33.4%
-6.6% vs TC avg
§103
20.6%
-19.4% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 837 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-3, 6-11, and 13-22 are under examination. Specification 2. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. (See page 24, line 4). Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// , www. or other browser-executable code. See MPEP § 608.01. Claim Rejections - 35 USC § 112 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7 and 16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Instant claim 7 depends from cancelled claim 4. Since claim 4 is cancelled, the metes and bounds of the instant claim is unclear. Instant claim 16 depends from cancelled claim 12. Since claim 12 is cancelled, the metes and bounds of the instant claim is unclear. Claim Rejections - 35 USC § 101 4. 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1-3, 6-11, and 13-22 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a judicial exception without significantly more. Claims 1-3, 6-11, and 13-22 are directed to method and system of determining the replication rate of a bacterial organism. As described in Alice Corp. Pty. Ltd. V. CLS Bank Int’l, 573 U.S._, 134 S. Cr. 2347, 110 U.S.P.Q.2d 1976 (2014), a two-step analysis is required in considering the patent eligibility of the claimed subject matter. The first step requires determining if the claimed subject matter is directed to a judicial exception. The instant claims require the mapping DNA sequence reads to a reference sequence database, identifying a plurality of bacterial organisms, measuring the read coverage at the genomic locations of phylogenetic marker genes, fitting a linear function for each of the bacterial organisms, obtaining the slope of the linear function, estimating the an expected read coverage at the origin of replication, estimating an expected read coverage at the terminus of replication, interpreting each of the bacterial organism a replication rate. These steps are mental steps or mathematical steps. Dependent claims 3, 6-11, 15-19 and 22 recite additional mental or mathematical steps or the data used in the judicial exception. The courts have found mathematical algorithms to be drawn to the judicial exception of an abstract idea (In re Grams, 888 F.2d 835, 12 U.S.P.Q.2d 1824 (Fed. Cir. 1989)). Thus, the instant claims are drawn to a judicial exception. This judicial exception is not integrated into a practical application. The instant claims do not recite an element that reflects an improvement in the functioning of a computer or other technology, an element that applies the judicial exception to effect a particular treatment, an element that implements the judicial exception with a particular machine, or an element that effects a transformation of a particular article to a different state or thing. The instant claims recites the steps of collecting a microbiome sample, extracting bacterial DNA, and performing PCR. However, these steps are extra solution data gathering steps. Extra solution data gathering steps are not sufficient to integrate the judicial exception into a practical application. The instant claims also recite The instant claims also recite a system, a sample collection module, DNA extraction module, a PCR amplification module, sequencer, memory, processor, and non-transitory machine-readable information storage medium. However, the instant claims do not recite structural limitations of these elements. Thus, the instant claims do not recite a particular machine that integrates the judicial exception into a practical application. The second part of the analysis requires determining if the claims include additional elements that are sufficient to amount to significantly more than the judicial exception. The instant claims recite the additional elements collecting a microbiome sample, extracting bacterial DNA, and performing PCR. However, these elements are well-understood, routine, and conventional activity in the life sciences (MPEP §2106(d) (II)). The elements of a system, a sample collection module, DNA extraction module, a PCR amplification module, sequencer, memory, processor, and non-transitory machine-readable information storage medium. However, these element are well-understood, conventional, and routine devices (MPEP §2106(d) (II); Specification, pages 37-39). Reciting such well-understood, routine, and conventional elements do not transform a judicial exception into patent eligible subject matter. In addition, the recitation of the specific types of data, to be used in the judicial exception, does not transform the abstract idea into a non-abstract idea. (See buySAFE, Inc. v Google, Inc. 765 F.3d 1350, 112 U.S.P.Q.2d 1093 (Fed.Cir.2014)). Furthermore, the elements taken as a combination are also well-understood, routine, and conventional, since the elements are merely specifying the types of data for a data gathering step and a generic device for implementing the judicial exception. Thus, the instant claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to JERRY LIN whose telephone number is (571)272-2561. The examiner can normally be reached T-F 7am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Olivia Wise can be reached at (571) 272-2249. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JERRY LIN/ Primary Examiner, Art Unit 1685
Read full office action

Prosecution Timeline

Jun 06, 2023
Application Filed
Jul 29, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12694948
Bioinformatics Systems, Apparatuses, and Methods for Performing Secondary and/or Tertiary Processing
5y 5m to grant Granted Jul 28, 2026
Patent 12694302
TECHNIQUES FOR RESOLVING DISCORDANT HER2 STATUS IN PATHOLOGY IMAGES FOR DIAGNOSING BREAST CANCER
4y 2m to grant Granted Jul 28, 2026
Patent 12680139
CANCER BIOMARKERS
2y 5m to grant Granted Jul 14, 2026
Patent 12676208
TUMOR ANTIGENICITY PROCESSING AND PRESENTATION
4y 5m to grant Granted Jul 07, 2026
Patent 12670971
Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform
5y 0m to grant Granted Jun 30, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
87%
With Interview (+15.0%)
3y 11m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 837 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month